GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyka Labs Ltd (NSE:LYKALABS) » Definitions » Cyclically Adjusted PB Ratio

Lyka Labs (NSE:LYKALABS) Cyclically Adjusted PB Ratio : (As of May. 12, 2025)


View and export this data going back to 1995. Start your Free Trial

What is Lyka Labs Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lyka Labs Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Lyka Labs's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyka Labs Cyclically Adjusted PB Ratio Chart

Lyka Labs Annual Data
Trend Jun14 Jun15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 3.79 5.25

Lyka Labs Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 5.25 - 6.86 -

Competitive Comparison of Lyka Labs's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Lyka Labs's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lyka Labs's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyka Labs's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lyka Labs's Cyclically Adjusted PB Ratio falls into.


;
;

Lyka Labs Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Lyka Labs's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Lyka Labs's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book=Book Value per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0/158.3229*158.3229
=0.000

Current CPI (Dec. 2024) = 158.3229.

Lyka Labs Quarterly Data

Book Value per Share CPI Adj_Book
201306 0.000 88.365 0.000
201309 28.019 91.042 48.725
201312 0.000 91.425 0.000
201406 24.427 94.103 41.097
201412 0.000 96.780 0.000
201506 19.954 99.841 31.642
201512 25.933 102.901 39.900
201603 20.527 102.518 31.701
201606 0.000 105.961 0.000
201609 18.425 105.961 27.530
201612 0.000 105.196 0.000
201703 17.110 105.196 25.751
201803 17.579 109.786 25.351
201806 0.000 111.317 0.000
201809 0.000 115.142 0.000
201812 0.000 115.142 0.000
201903 15.286 118.202 20.474
201906 0.000 120.880 0.000
201909 13.944 123.175 17.923
201912 0.000 126.235 0.000
202003 -5.000 124.705 -6.348
202006 0.000 127.000 0.000
202009 -8.669 130.118 -10.548
202012 0.000 130.889 0.000
202103 -8.992 131.771 -10.804
202106 0.000 134.084 0.000
202109 7.689 135.847 8.961
202112 0.000 138.161 0.000
202203 4.649 138.822 5.302
202206 0.000 142.347 0.000
202209 4.701 144.661 5.145
202212 0.000 145.763 0.000
202303 14.806 146.865 15.961
202306 0.000 150.280 0.000
202309 20.616 151.492 21.546
202312 0.000 152.924 0.000
202403 20.597 153.035 21.309
202406 0.000 155.789 0.000
202409 27.714 157.882 27.791
202412 0.000 158.323 0.000

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lyka Labs  (NSE:LYKALABS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Lyka Labs Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Lyka Labs's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lyka Labs Business Description

Traded in Other Exchanges
Address
30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.

Lyka Labs Headlines

No Headlines